famectinib

Famectinib (HL-085) is an orally bioavailable, potent, and selective small molecule inhibitor of mitogen-activated protein kinase kinase 1 and 2 (MEK1/2). Developed by Shanghai Haihe Biopharma, it targets the MAPK/ERK signaling pathway, which is frequently overactivated in various malignancies due to mutations in RAS or RAF. By inhibiting MEK1/2, famectinib blocks downstream signaling that promotes tumor cell proliferation and survival. It is currently being evaluated in clinical trials for the treatment of advanced solid tumors, including NRAS-mutant melanoma and recurrent or metastatic cervical cancer. In clinical studies, it is often investigated as a monotherapy or in combination with immune checkpoint inhibitors such as the PD-1 inhibitor camrelizumab.

Other names

法美替尼